Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07428746 · ClinicalTrials.gov registry record · Phase 3
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
A Phase 3 study, sponsored by Emory University.
- Not yet
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT07428746 is a Phase 3 study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT07428746, a Phase 3 study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing
Interventions
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07428746
The ClinicalTrials.gov registry entry for NCT07428746 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semaglutide is the first listed.
NCT07428746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07428746 about?
NCT07428746 is a clinical study titled "Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes". The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA...
What is the current status of trial NCT07428746?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2026-04. Estimated completion is 2028-11.
What interventions are being tested in trial NCT07428746?
The interventions under investigation include: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07428746?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.